BioSpace News Archive

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a new presentation time for BMO’s Virtual 2020 Prescriptions for Success Healthcare Conference, which is being held on Tuesday, June 23. John Tucker, chief executive off

Alpine Immune Sciences grants AbbVie option to license worldwide rights to ALPN-101, a phase 2-ready, first-in-class dual CD28/ICOS costimulation antagonist, building on AbbVie’s commitment to developing novel therapies in Immunology - Alpine Immune Sciences to receive $60 million in an upfront cash payment; eligible to receive up to $805 million for exercise of the option and success-based development, regulatory and commercial milestones

XP-3924 resulted in a 62% reduction of hyperglycemia after a glucose challenge XP-3924 showed improved glucose control when compared to Humulin® R alone XP-3924 showed promising glucose control when compared to both Humulin® R and co-administered injections of Humulin® R and Symlin® XP-3924 was observed to be safe and well tolerated in this study CHICAGO--( BUSINESS WIRE )-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty

The reopening of commercial buildings in the wake of COVID-19 poses the unintended risk of Legionnaire’s disease––and Flow-Tech is poised to be a key component of the long-term solution.

Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, today announces that Predictive’s TumorGenesis division sold its first order of its unique ovarian cancer cell culture media for cancer cells collected from patient derived samples

Support for Program Underscores Align Technology’s Commitment to Advancing Health Solutions and Improving the Lives of Patients in the Asia Pacific Region

Aegea Biotechnologies, Inc. (“Aegea”) ( www.aegeabiotech.com ) , a biotechnology company focusing on the development and commercialization of next generation nucleic acid clinical diagnostic technologies, announces progress on the development of two COVID-19 d

Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Japan Patent Office (JPO) has issued a notice of allowance for a patent application covering ALLOCETRA TM , the company’s immunotherapy product candidate. Upon issuance, the new patent will provide additional intellectual property protection around methods of using ALLOCETRA TM and pharmaceutical compositions comprising the same. The company expec

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the first subject has been successfully dosed in a Phase 1b/2 clinical trial of dual glucagon-like peptide 1 receptor and the glucagon receptor agonist in China.

IMpassion031 data will be discussed with health authorities globally, including the U.S. Food and Drug Administration and the European Medicines Agency